09:57 AM EST - Nordion Inc. : announced that it has received U.S. Food and Drug Administration (FDA) approval to conduct a Phase III clinical trial for TheraSphere® under an Investigational Device Exemption (IDE). The trial will examine the safety and effectiveness of TheraSphere when the treatment is added to standard kinase inhibitor therapy in patients with unresectable hepatocellular carcinoma (HCC), the most common form of inoperable primary liver cancer. Nordion Inc.
shares T.NDN are trading down $0.01 at $11.10.
